Summary
As the world continues to deal with COVID-19, economies are moving into recession, official counts of cases and deaths from COVID-19 have passed 4,000,000 and 280,000 at the time of this report. Many government announced a plan on reopening the national economy, but many countries are still at the stage of rising.
On a more positive note, we are already seeing signs of recovery as the COVID-19 risk is declining in China. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. XYZResearch published a report for global Nuclear Medicine/Radiopharmaceuticals market in this environment.
In terms of revenue, this research report indicated that the global Nuclear Medicine/Radiopharmaceuticals market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Nuclear Medicine/Radiopharmaceuticals industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Cardinal Health aims at producing XX Nuclear Medicine/Radiopharmaceuticals in 2020, with XX % production to take place in global market, Mallinckrodt accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Nuclear Medicine/Radiopharmaceuticals Market by XYZResearch Include
China
EU
USA
Japan
India
Korea
South America
Competitive Analysis; Who are the Major Players in Nuclear Medicine/Radiopharmaceuticals Market?
Cardinal Health
Mallinckrodt
GE Healthcare
Lantheus Medical Imaging
Bayer
Bracco Imaging
Eczacibasi-Monrol Nuclear Products
Nordion
Advanced Accelerator Applications
IBA Molecular Imaging
Major Type of Nuclear Medicine/Radiopharmaceuticals Covered in XYZResearch report:
Diagnostic (SPECT - Technetium, PET - F-18)
Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)
Application Segments Covered in XYZResearch Market
Oncology
Thyroid
Cardiology
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Nuclear Medicine/Radiopharmaceuticals Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Diagnostic (SPECT - Technetium, PET - F-18) -Product Introduction and Major Manufacturers
1.1.2 Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Regional Market
2.1 Regional Market Share in Terms of Production (2019-2026)
2.2 Regional Market Share in Terms of Revenue (2019-2026)
2.3 Regional Market Share in Terms of Consumption (2019-2026)
3 Global Nuclear Medicine/Radiopharmaceuticals Market Assessment by Type
3.1 Global Nuclear Medicine/Radiopharmaceuticals Production by Type (2015-2026)
3.2 Global Nuclear Medicine/Radiopharmaceuticals Revenue by Type (2015-2026)
3.3 China Nuclear Medicine/Radiopharmaceuticals Production and Revenue by Type (2015-2026)
3.4 EU Nuclear Medicine/Radiopharmaceuticals Production and Revenue by Type (2015-2026)
3.5 USA Nuclear Medicine/Radiopharmaceuticals Production and Revenue by Type (2015-2026)
3.6 Japan Nuclear Medicine/Radiopharmaceuticals Production and Revenue by Type (2015-2026)
3.7 India Nuclear Medicine/Radiopharmaceuticals Production and Revenue by Type (2015-2026)
3.8 Korea Nuclear Medicine/Radiopharmaceuticals Production and Revenue by Type (2015-2026)
3.9 South America Nuclear Medicine/Radiopharmaceuticals Production and Revenue by Type (2015-2026)
4 Global Nuclear Medicine/Radiopharmaceuticals Market Assessment by Application
4.1 Historical & Forecast Global Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
4.2 Historical & Forecast China Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
4.3 Historical & Forecast EU Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
4.4 Historical & Forecast USA Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
4.5 Historical & Forecast Japan Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
4.6 Historical & Forecast India Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
4.7 Historical & Forecast Korea Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
4.8 Historical & Forecast South America Nuclear Medicine/Radiopharmaceuticals Consumption, Different Application Field (2015-2026)
5 Global Nuclear Medicine/Radiopharmaceuticals Average Price Trend
5.1 Market Price for Each Type of Nuclear Medicine/Radiopharmaceuticals in China (2015-2026)
5.2 Market Price for Each Type of Nuclear Medicine/Radiopharmaceuticals in EU (2015-2026)
5.3 Market Price for Each Type of Nuclear Medicine/Radiopharmaceuticals in USA (2015-2026)
5.4 Market Price for Each Type of Nuclear Medicine/Radiopharmaceuticals in Japan (2015-2026)
5.5 Market Price for Each Type of Nuclear Medicine/Radiopharmaceuticals in India (2015-2026)
5.6 Market Price for Each Type of Nuclear Medicine/Radiopharmaceuticals in Korea (2015-2026)
5.7 Market Price for Each Type of Nuclear Medicine/Radiopharmaceuticals in South America (2015-2026)
6 Value Chain (Impact of COVID-19)
6.1 Nuclear Medicine/Radiopharmaceuticals Value Chain Analysis
6.1.1 Upstream
6.1.2 Downstream
6.2 COVID-19 Impact on Nuclear Medicine/Radiopharmaceuticals Industry
6.2.1 Industrial Policy Issued Under the Epidemic Situation
6.3 Cost-Under the Epidemic Situation
6.3.1 Cost of Raw Material
6.4 Channel Analysis
6.4.1 Distribution Channel-Under the Epidemic Situation
6.4.2 Distributors
7 Nuclear Medicine/Radiopharmaceuticals Competitive Analysis
7.1 Cardinal Health
7.1.1 Cardinal Health Company Profiles
7.1.2 Cardinal Health Product Introduction
7.1.3 Cardinal Health Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.1.4 SWOT Analysis
7.2 Mallinckrodt
7.2.1 Mallinckrodt Company Profiles
7.2.2 Mallinckrodt Product Introduction
7.2.3 Mallinckrodt Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.2.4 SWOT Analysis
7.3 GE Healthcare
7.3.1 GE Healthcare Company Profiles
7.3.2 GE Healthcare Product Introduction
7.3.3 GE Healthcare Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.3.4 SWOT Analysis
7.4 Lantheus Medical Imaging
7.4.1 Lantheus Medical Imaging Company Profiles
7.4.2 Lantheus Medical Imaging Product Introduction
7.4.3 Lantheus Medical Imaging Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.4.4 SWOT Analysis
7.5 Bayer
7.5.1 Bayer Company Profiles
7.5.2 Bayer Product Introduction
7.5.3 Bayer Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.5.4 SWOT Analysis
7.6 Bracco Imaging
7.6.1 Bracco Imaging Company Profiles
7.6.2 Bracco Imaging Product Introduction
7.6.3 Bracco Imaging Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.6.4 SWOT Analysis
7.7 Eczacibasi-Monrol Nuclear Products
7.7.1 Eczacibasi-Monrol Nuclear Products Company Profiles
7.7.2 Eczacibasi-Monrol Nuclear Products Product Introduction
7.7.3 Eczacibasi-Monrol Nuclear Products Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.7.4 SWOT Analysis
7.8 Nordion
7.8.1 Nordion Company Profiles
7.8.2 Nordion Product Introduction
7.8.3 Nordion Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.8.4 SWOT Analysis
7.9 Advanced Accelerator Applications
7.9.1 Advanced Accelerator Applications Company Profiles
7.9.2 Advanced Accelerator Applications Product Introduction
7.9.3 Advanced Accelerator Applications Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.9.4 SWOT Analysis
7.10 IBA Molecular Imaging
7.10.1 IBA Molecular Imaging Company Profiles
7.10.2 IBA Molecular Imaging Product Introduction
7.10.3 IBA Molecular Imaging Nuclear Medicine/Radiopharmaceuticals Production, Revenue (2015-2020)
7.10.4 SWOT Analysis
8 Conclusion